A review of the epidemiology, diagnosis, treatment, vaccines and economic impact of human monkeypox (Mpox) outbreaks

The current monkeypox outbreak is a public health emergency of international concern and is coming in the wake of the SARS-CoV-2 pandemic. Human monkeypox is a viral zoonotic infection caused by monkeypox virus, an enveloped double-stranded DNA virus of the genus Orthopoxvirus and family Poxviridae that also contain smallpox, cowpox, Orf, and vaccinia viruses. Online databases including PubMed, Google Scholar and Web of Science were searched to obtain relevant publications on the epidemiology, treatment, vaccines and the economic impacts of the current monkeypox (Mpox) outbreak.

Monkeypox (Mpox) re-emergence: prevalence, diagnostics, countermeasures, and its global effect

While the world is still trying to emerge from the crisis due to the COVID-19 pandemic, and all the nations are trying to nullify the repercussions caused by it;another outbreak known as the monkeypox virus (MPXV) has recommenced. Human monkeypox, a rare viral zoonosis (an infectious disease that can be transferred from non-human animals to humans), is caused by the MPXV, a member of the genus Orthopoxvirus (family Poxviridae, subfamily Chordopoxvirinae). Since eradicating smallpox globally in 1977, monkeypox has been the primary orthopoxvirus infection in humans. On July 14, 2022, the first case in India was reported in the Kollam district of Kerala. It manifests with the same symptoms as smallpox, including flu-like symptoms, fever, malaise, headache, back pain, and a characteristic rash. New medications have shown promising results, but more study is needed for the drug's efficacy in endemic settings. The monkeypox virus is a high-danger pathogen that causes a significant disease for public health. Consequently, there is a pressing need to develop surveillance capabilities that can yield valuable data for creating suitable preventative, preparedness, and response operations. © 2023,.

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.

Although one member of the poxvirus family, variola virus, has caused one of the most devastating human infections worldwide, smallpox, the knowledge gained over the last 30 years on the molecular, virological and immunological mechanisms of these viruses has allowed the use of members of this family as vectors for the generation of recombinant vaccines against numerous pathogens. In this review, we cover different aspects of the history and biology of poxviruses with emphasis on their application as vaccines, from first- to fourth-generation, against smallpox, monkeypox, emerging viral diseases highlighted by the World Health Organization (COVID-19, Crimean-Congo haemorrhagic fever, Ebola and Marburg virus diseases, Lassa fever, Middle East respiratory syndrome and severe acute respiratory syndrome, Nipah and other henipaviral diseases, Rift Valley fever and Zika), as well as against one of the most concerning prevalent virus, the Human Immunodeficiency Virus, the causative agent of Acquired Immunodeficiency Syndrome. We discuss the implications in human health of the 2022 monkeypox epidemic affecting many countries, and the rapid prophylactic and therapeutic measures adopted to control virus dissemination within the human population. We also describe the preclinical and clinical evaluation of the Modified Vaccinia virus Ankara and New York vaccinia virus poxviral strains expressing heterologous antigens from the viral diseases listed above. Finally, we report different approaches to improve the immunogenicity and efficacy of poxvirus-based vaccine candidates, such as deletion of immunomodulatory genes, insertion of host-range genes and enhanced transcription of foreign genes through modified viral promoters. Some future prospects are also highlighted.

Serological responses to smallpox A33 antigen and monkeypox A35 antigen in healthy people and people living with HIV-1 from Guangzhou, China.

People are expected to have been previously vaccinated with a Vaccinia-based vaccine, as until 1980 smallpox vaccination was a standard protocol in China. It is unclear whether people with smallpox vaccine still have antibody against vaccinia virus (VACV) and cross-antibody against monkeypox virus (MPXV). Herein, we assessed the binding antibodies with antigen of VACV-A33 and MPXV-A35 in the general population and HIV-1 infected patients. Firstly, we detected VACV antibody with A33 protein to evaluate the efficiency of smallpox vaccination. The result show that 29% (23 of 79) of hospital staff (age ≥ 42 years) and 63% (60 of 95) of HIV-positive patients (age ≥ 42 years) from Guangzhou Eighth People's Hospital were able to bind A33. However, among the subjects below 42 years of age, 1.5% (3/198) of the hospital volunteer samples and 1% (1/104) of the samples from HIV patients were positive for antibodies against A33 antigen. Then, we assessed the specific cross-reactive antibodies against MPXV A35 protein. 24% (19 of 79) hospital staff (age〉 = 42 years) and 44% (42 of 95) of HIV-positive patients (age〉 = 42 years) were positive. 98% (194/198) of the hospital staff and 99% (103/104) of the HIV patients had no A35-binding antibodies. Further, we found significant sex differences for the reactivity to A35 antigen were observed in HIV population, but no significant sex differences in hospital staff. Further, we analyzed the positivity rate of anti-A35 antibody of men who have sex with men (MSM) and non-MSM in HIV patients (age〉 = 42years). We found that 47% of no-MSM population and 40% of MSM population were positive for A35 antigen, with no significant difference. Lastly, we found only 59 samples were positive for anti-A33 IgG and anti-A35 IgG in all participants. Together, we demonstrated A33 and A35 antigens binding antibodies were detected in HIV patients and general population who were older than 42 years, and cohort studies only provided data of serological detection to support early response to monkeypox outbreak.

The Art of Stem Cell-Based Therapy.

Potency assays represent crucial experiments at the hub of the comprehensive complexity surrounding cell therapy. Moreover, numerous factors beyond biological and scientific considerations are involved in achieving successful potency assays that fulfil regulatory authority approval for a new advanced therapy medicinal product. Though this can mean a frustratingly long period of discovery and development, progress in cell therapy is nowadays proceeding remarkably quickly, assisted by the potency assay rigorously placing emphasis on the need to critically analyse the key factor/s responsible for the therapeutic mechanism of action. History has shown that it can take many decades for there to be an improved understanding of a mechanism of action. Yet the chasing of precise targets has revolutionised medicine, with no clearer example than approaches to viral pandemics. The centuries involved in the eradication of smallpox have paved the way for an unprecedented pace of vaccine development for the Covid-19 pandemic. Such extraordinary accomplishments foster encouragement that similarly for stem cell-based therapy, our scientific knowledge will continue to improve apace. This chapter focuses on the art of experimentation and discovery, introducing potency assay requisites and numerous factors that can influence potency assay outcomes. A comprehensive understanding of potency assays and their development can hasten the provision of new cell therapies to help resolve burdensome diseases of unmet medical need.

Sexual orientation was associated with intention to be vaccinated with a smallpox vaccine against mpox: A cross-sectional preliminary survey in Japan.

This survey aimed to assess the prevalence of intention to receive smallpox vaccine against mpox and its relationship with sexual orientation in Japan. A cross-sectional online survey was conducted in September-October 2022, with 12,900 assigned males and 13,413 assigned females participating. Modified Poisson regression analyses were performed to determine the relationship between vaccine willingness and sexual orientation, adjusting for socioeconomics, trust in government, COVID-19 vaccination status, and frequency of brothel visits. Vaccine willingness was higher in homosexual respondents than heterosexual counterparts, with proportions of 23.1 % among assigned males and 13.4 % among assigned females. Homosexual orientation was significantly associated with vaccine willingness, with prevalence ratios of 1.37 (95 % CI: 1.23-1.54) among assigned males and 1.34 (95 % CI: 1.13-1.59) among assigned females. These findings highlight the need for targeted vaccine promotion campaigns and ongoing monitoring of attitudes towards mpox and vaccine compliance in high-risk groups.

Comparison between COVID-19 and monkeypox vaccine uptake in a diverse London HIV cohort

Background: The COVID-19 pandemic caused millions of deaths, its impact lessened with effective vaccines and treatments. The subsequent monkeypox outbreak posed another global threat, disproportionately affecting men who have sex with men (MSM), with concerns around increasing community stigma. Vaccinating at risk groups is vital in minimising COVID-19 and monkeypox transmissions and adverse sequalae. Our HIV clinic serves a diverse population in a deprived area with a large immigrant population and high level of co-morbidities, associated with poorer outcomes. We explored factors associated with COVID-19 and monkeypox vaccine uptake. Method(s): We reviewed COVID-19 vaccine first, second and third/booster uptake and first smallpox vaccine among MSMs attending our HIV clinic. Monkeypox vaccination is a two-dose course. Initial limited vaccine availability meant first monkeypox vaccine was prioritised for all eligible patients;we therefore analysed first monkeypox vaccination uptake. 186 MSM PLWH were identified. 164 were included in our analysis;22 were excluded due to insufficient vaccination information. Data was recorded contemporaneously in patients' records. COVID-19 vaccine uptake was verified using NHS Summary Care Record and London Care Record. Data on age and ethnicity was collected. Result(s): Demographics: Age: mean 42.9 years, 49% <=40 years, 51% >40 years Ethnicity: 55% White, 26% Black, 5% Asian, 2% mixed, 7% other, 4% not stated COVID-19 vaccination uptake reached statistical significance between age groups: <=40y 53%, >40y 80% (p = 0.001) and ethnicities: White 73%, Black 50%, Asian 67% (p = 0.026). Monkeypox vaccination uptake did not reach significance: <40y 26%, >40y 29%;ethnicity: White 31%, Black 24%, Asian 33%. Additionally, COVID-19 vaccinated patients were not statistically significantly more likely to accept monkeypox vaccination. Conclusion(s): Monkeypox vaccination uptake was similar across ages and ethnicities. However, monkeypox vaccination uptake was considerably lower than COVID-19 vaccination. Further work is needed to identify and engage at risk groups and address obstacles affecting monkeypox vaccination in marginalised communities. Lessons from COVID vaccination campaigns should be employed to reach unvaccinated high-risk MSMs. (Table Presented).

Viral vector vaccines: efforts to develop vaccines against emerging infectious diseases

Vaccines are one of the most effective means of preventing viral infections. Since Edward Jenner invented the world's first vaccine in 1796, against smallpox, various types of vaccine have been developed, including inactivated vaccines, attenuated live vaccines, recombinant protein vaccines, viral vector vaccines and nucleic acid vaccines. Viral vector vaccines and nucleic acid vaccines （mRNA vaccines and DNA vaccines） have been developed most recently. In these vaccines, genes encoding viral proteins that serve as antigens are introduced into the body. The viral vector is an excellent vaccine delivery system that efficiently delivers antigen genes to target cells, and has been utilized for vaccine development against a variety of emerging infectious diseases, including AIDS, malaria, Ebola hemorrhagic fever, dengue fever, and most recently COVID-19. Here, we provide an overview of viral vector vaccines and discuss recent efforts to develop vaccines against emerging infectious diseases.Alternate :抄録ウイルス性感染症を予防するうえで、ワクチンは最も有効な手段の一つである。1976年、エドワード・ジェンナーが世界初のワクチンである種痘を発明して以来、さまざまなウイルス性感染症に対して、不活化ワクチン、弱毒生ワクチン、組換えタンパクワクチン、ウイルスベクターワクチン、核酸ワクチンなど、多様なプラットフォームに基づくワクチン開発が進められてきた。本稿では、数あるワクチンプラットフォームの中から、ウイルスベクターワクチンに着目して、いくつかの例をあげて概説するとともに、近年、国際的な問題となっている新興感染症に対するワクチン開発などの取り組みについても述べる。

Introduction: A Call to Engage with Denial

Cruz was appointed as head of the General Directorate of Public Health in 1903, at a time when yellow fever had killed a thousand people in the city of Rio de Janeiro alone the previous year. The newspaper printed a portrait of a man suffering from a grisly tumor in late October 1904 and claimed that vaccines caused his ailment.8 The newspaper explained that vaccines were the, "monster that pollutes the pure and innocent blood of our children with the vile excretions expelled from sick animals, of a nature that contaminates the system of any living being. "9 This newspaper article argued that it was providing the public with the "information" it needed to evaluate the government's mandates.10 It is an example of coordinated efforts to spread mis/disinformation by the press as part of the effort to create a public campaign against Alves' public health policy. Uprisings, which were also taking place in the industrial workers' neighborhoods and the Afro-Brazilian districts with fierce hand-to-hand combat, were eventually put down and citizens were pressured to retreat by the army advancing by land and the threat of bombardment by the navy docked just offshore.11 The state used repressive measures (imprisonment, beatings, interrogation, and internal exile) and put the instigators, including Senator Lauro Sodré and military officers, on trial following the uprising.12 The government declared a "state of siege" and the uprising was controlled in three days.13 However, although the government had survived the assault, the Alves administration was forced to abandon its vaccine mandate and smallpox continued to plague the country for several more years, slowing plans to modernize.

Epidemics and Society: From the Black Death to the Present by Frank M. Snowden (review)

Thematically, the book concentrates on the intellectual, cultural, and public health contexts of epidemics, with frequent attention to the interplay of war and disease. The main disappointment (for me) in his choices of what to include and what to leave out is the extremely thin treatment of the disease experience of the Americas in the wake of Columbus. For readers interested primarily in Europe's cultural, scientific, and public health engagement with epidemics, this book will serve admirably.

Past, present and future of infectious diseases

The history of humankind has been a battle against infectious diseases, and highly lethal viral infections have appeared many times. Even in Japan, one-fourth of the population was lost due to smallpox during the Nara period. In the modern era, effective vaccines and drugs were developed, and everyone was optimistic that infectious diseases could be eradicated from the earth by the end of the 20th century. However, infectious diseases such as AIDS, influenza, SARS, and MERS emerged. In particular, the novel coronavirus pandemic that occurred in Wuhan, China, at the end of 2019 exposed the vulnerability of modern society to infectious diseases. Furthermore, infectious diseases are undergoing significant changes due to human factors such as globalization and the destruction of nature. In this review, I would like to outline the infectious diseases that humans have experienced so far and introduce the fight against the new coronavirus and future infectious disease countermeasures.Alternate :抄録人類の歴史は感染症との戦いであり、致死性の高いウイルス感染症が幾度となく出現し、日本でも奈良時代に天然痘により当時の日本の人口の4分の1が失われた。近代に入ると有効なワクチンや薬剤が開発され、20世紀中には地球上から感染症を根絶できると誰もが楽観視していたが、エイズ、インフルエンザ、SARS、MERS等の感染症が出現し、特に、2019年の暮れに中国武漢で発生した新型コロナウイルスのパンデミックは猖獗を極め、現代社会がいかに感染症に対して無力であるかを思い知らされた。さらに、グローバリゼーションや自然破壊等の人的要因によって感染症は大きく変容している。本稿では、これまでに人類が経験した感染症を概説し、新型コロナウイルスとの戦い、そして今後の感染症対策について解説したい。

A Review on Recent Monkey Pox Outbreak in 2022

Monkey pox, a zoonotic disease with clinical symptoms resembling smallpox, unexpectedly broke out and spread over the world after the outbreak of COVID-19, severely affecting several of the continents of the world. Monkey pox is currently a member of the genus otrhopox virus, which is a member of the sub family chorodoxvirinae. According to the available knowledge, small mammals and rodents have all been identified as potential sources of the monkey [ox virus]. The disease is characterized by a short febrile illness with lymphadenopathy followed by a rash which spreads centrifugally and passes through phases of macules, papules, vesicles, and pustules. Recovery occurs in most patients within 2-4 wk. Complications are more likely in children, pregnant women, and the immunocompromised. Specific diagnosis is by detection of viral DNA by PCR.Tecovirimat, brincidofovir, and cidofoviir are the medications used to treat monkey pox, immunoglobulin and new compounds are the vaccinations. This review will introduce a general overview of MPXV and describe the epidemiology, clinical features, evaluation, and treatment of monkey pox patients.Copyright © Journal of Global Trends in Pharmaceutical Sciences.

Human monkeypox virus in the shadow of the COVID-19 pandemic.

BACKGROUND: The end of smallpox in 1980 and the subsequent stopping of vaccination against smallpox was followed by the emergence of monkeypox (mpox), a viral disease of animal origin, meaning that it is transmitted from animal to human. The symptoms of mpox are similar to smallpox, except that they are less severe in terms of clinical features. In the case of public health, the mpox virus is one of the most important orthopoxviruses (such as variola, cowpox, and vaccinia) that come from the family Poxviridae. Mpox occurs mostly in central Africa and sometimes in tropical rainforests or some urban areas. Also, there are threats other than COVID-19, that must be addressed and prevented from spreading, as there has been an outbreak of mpox cases since May 7, 2022, throughout the USA, Europe, Australia, and part of Africa. OBJECTIVES: In this review, we will discuss mpox between the past, the present and during the COVID-19 pandemic. Also, it offers an updated summary of the taxonomy, etiology, transmission, and epidemiology of mpox illness. In addition, the current review aims to highlight the importance of emerging pandemics in the same era such as mpox and COVID-19. METHODS: A literature search was done for the study using online sources like PubMed and Google Scholar. Publications in English were included. Data for study variables were extracted. After the duplicate articles were eliminated, full-text screening was performed on the papers' titles and abstracts. RESULTS: The evaluation included a series documenting mpox virus outbreaks, and both prospective and retrospectiveinvestigations. CONCLUSIONS: monkeypox is a viral disease caused by the monkeypox virus (MPXV), which is primarily found in central and western Africa. The disease is transmitted from animals to humans and presents symptoms similar to those of smallpox, including fever, headache, muscle aches, and a rash. Monkeypox can lead to complications such as secondary integument infection, bronchopneumonia, sepsis, and encephalitis, as well as corneal infection that can result in blindness. There is no specific clinically proven treatment for monkeypox, and treatment is primarily supportive. However, antiviral drugs and vaccines are available for cross-protection against the virus, and strict infection control measures and vaccination of close contacts of affected individuals can help prevent and control outbreaks.

Monkeypox: a global health emergency.

Over the past 2 years, the world has faced the impactful Coronavirus Disease-2019 (COVID-19) pandemic, with a visible shift in economy, medicine, and beyond. As of recent times, the emergence of the monkeypox (mpox) virus infections and the growing number of infected cases have raised panic and fear among people, not only due to its resemblance to the now eradicated smallpox virus, but also because another potential pandemic could have catastrophic consequences, globally. However, studies of the smallpox virus performed in the past and wisdom gained from the COVID-19 pandemic are the two most helpful tools for humanity that can prevent major outbreaks of the mpox virus, thus warding off another pandemic. Because smallpox and mpox are part of the same virus genus, the Orthopoxvirus genus, the structure and pathogenesis, as well as the transmission of both these two viruses are highly similar. Because of these similarities, antivirals and vaccines approved and licensed in the past for the smallpox virus are effective and could successfully treat and prevent an mpox virus infection. This review discusses the main components that outline this current global health issue raised by the mpox virus, by presenting it as a whole, and integrating aspects such as its structure, pathogenesis, clinical aspects, prevention, and treatment options, and how this ongoing phenomenon is being globally approached.

Migration and spread of infectious diseases: From the origin of Homo sapiens up to the Anthropocene

A typifying characteristic of Homo sapiens is its ability to walk upright, which allowed humans to move about in grasslands, enabling them to leave the forests of central Africa and populate the rest of Africa and later the world, a success story like no other. Africa is the place of origin of Homo sapiens. The first major migration of anatomically modern humans, known as the Out-of-Africa migration, was the first of many migratory events of Homo sapiens that continue up to the current era that shaped the world and society. This article aims to describe the defining role of human migration in spreading infectious diseases from pre-history to the present. In future, infectious diseases will continue to spread through migration. However, by contrast, the spread of diseases will be exacerbated due to the opportunities provided in the Anthropocene epoch and will become progressively more challenging. Migration is a term that encompasses the simultaneous movement of large numbers or groups of people away from their original place of living and for a specific reason. The main reasons for migration are emigration/immigration, forced displacement, slavery, migrant labour, asylum seeking and refugees. In addition, war, conflict, and environmental disasters such as droughts, famine and overpopulation are other common causes of migration. Migration is usually unplanned;it happens without warning or advanced planning and is accompanied by a large-scale disruption in the socio-economic structure, health, and well-being of the migrants and/or other affected groups. Such major disruptions to individuals' normal living can weaken the immune system, leading to increased susceptibility to infectious diseases. In addition, temporary housing during migration can often also result in humanitarian disasters that increase opportunities for the transmission of infectious diseases. Migrants are also at risk of contracting new or previously-unencountered diseases prevalent in their chosen resettlement area. Conversely, migrants can carry with them microorganisms absent in the resettlement area. An example of this is the smallpox virus that was brought to South America by the Spanish colonisers. At that stage, poxvirus was absent in this continent, and the indigenous populations had no immunity to the pathogen. The transmission of the poxvirus by colonizers to indigenous populations almost destroyed the indigenous populations of the time. A form of migration that emerged more recently is travel. Travel migration is defined as the large number of unrelated individuals who travel simultaneously across the globe for work or pleasure. Travel migration has been enabled by advances in the speed by which air and train travel takes place. This results in large numbers of individuals being transported across the globe in a short period and over long distances. Travel by water, air and land resulted in the world's population being highly interconnected through the mingling of large numbers of people from geographically remote places but in a relatively short period. Travelling connects people and diseases across the globe. Examples of pathogens that spread through migration and that cause major infectious diseases include the smallpox virus, the human immuno-deficiency virus (HIV), and coronaviruses that cause Middle Eastern respiratory syndrome (MERS), coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS). Mycobacterium tuberculosis, the cause of tuberculosis, and Helicobacter pylori, which can cause gastric ulcers, are among the oldest known bacteria that infect humans and were already present in humans when the Out-of-Africa migration occurred. These two pathogens were carried with humans as they migrated and populated new areas of the world, and both have been present in large numbers of humans over millennia. These two organisms can only spread through very close contact between humans and have no host outside the body;therefore, they are great examples of how migration distributes infectious diseases across the world. Mycobacterium tuberculosis is exceptionally well-adapted to spread and cause disease among individuals with lower immunity, such as migrants. Poor housing conditions and crowding, which invariably result from migration due to humanitarian disasters, advance the transmission of pathogens such as tuberculosis. Major lifestyle changes of humans occurred from the Paleolithic to the Neolithic after the Out-of-Africa migration, which directly or indirectly benefited the transmission of diseases. During the Neolithic, animals were domesticated, and agriculture started, allowing people to settle down and establishing the first towns and cities. The domestication of animals created an opportunity for pathogens to cross from animals to humans and adapt to the new host to cause new infectious diseases in humans, called zoonosis. The Anthropocene dawned when deforestation, mining, farming, and other human activities left their mark. As a result, the Anthropocene offers unique opportunities for the emergence and spread of infectious diseases: firstly, by zoonosis or the transmission of diseases from animals to humans, and secondly, the spread of the diseases through migration. Furthermore, changes in the weather and climate can lead to environmental migration. This occurs when people need to abandon their normal place of living because of severe weather events such as droughts and ice ages. Labour migration was responsible for the spread of HIV from its place of origin in Africa. This virus initially landed in humans through inter-species cross-over from primates to humans in the 1950s from eating semi-cooked bush meat. As a result, it became established in the indigenous populations of Africa. HIV is a sexually transmitted disease amongst humans, and migratory labourers from Haiti were infected with the virus while working in the Congo, where they transmitted the virus to people in Haiti upon their return. The MERS and SARS coronaviruses became human pathogens due to bat-human species cross-over, probably due to eating bush meat. However, the rapid distribution of these two viruses to other areas of the world was enabled through travel migration and the highly connected world population. Similarly, the extremely rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon its discovery in December 2019 was partly due to travel migration. In future, the negative impact of infectious diseases can be prevented by having disaster preparedness plans to protect the health and well-being of migrants and resident populations. However, events that can potentially be disastrous are difficult to pre-empt: the world was largely unprepared on how to respond to the rapid spread of SARS-CoV-2 and how to control the ensuing pandemic. Other recent examples of similar unforeseen events are the Ukraine-Russian conflict that started in March 2022, which caused many people from Ukraine to flee to other countries for safety. The second example is the heavy rain of April 2022 in the KwaZulu-Natal Province of South Africa, which caused massive destruction of houses and infrastructure, resulting in affected people being displaced. In both cases, the reasons for migration can have a detrimental impact on the health of the affected people, which renders them susceptible to disease transmission.

Waking Up to Monkeypox in the Midst of COVID-19.

The first incidence of the monkeypox virus (MPXV) was reported in a Danish research facility. Even though first discovered in monkeys, rodents account for the largest reservoir of the disease. It is an encapsulated, brick-shaped double-stranded DNA virus strongly related to the smallpox virus. The risk of acquiring MPXV has been found to be inversely related to smallpox vaccination. Although the cases were initially restricted to African countries, they were first reported outside Africa in the early 2000s. MPXV is transmitted through close personal contact, most commonly through direct skin-skin contact. The fatality rates associated with the MPXV tend to vary in different regions, with Congo clad basin having the highest mortality rate. The majority of the cases of MPXV have been reported in men who have sex with men. Although optimal infection control and treatment strategies are under investigation, the current management focus is on immunization and the isolation of patients. Effective control strategies are based on implementing a method of contact tracing, quarantining exposed and infected individuals, and using vaccines. There is no proven cure for MPXV, and most infected patients recover without medical intervention. Extensive studies are being conducted to determine the efficacy of antivirals in managing MPXV, with tecovirimat being the first antiviral medication approved by the Food and Drug Administration (FDA) to manage MPXV. The smallpox vaccine has traditionally been thought of as the most effective method of controlling the infection, possibly due to the similarities between the two viruses. However, numerous obstacles prevent the effective control of MPXV, including social isolation and stigma, poor understanding of the disease dynamics, lack of adequate patient education, and public health strategies.

Guidelines on epidemics in Mexico. Historical perspective.

A perspective of epidemics and pandemics in Mexico is offered, focusing on three time periods, namely, end of the 18th century, the 20th century, and the 21st century, in order to analyze how they were approached by health and government authorities, as well as the challenges they have represented. Historical documentary sources were consulted and, in current cases, participation in them was analyzed. Epidemiological and social historical methodologies were combined. The presence of epidemics in Mexico is a constant on its evolution, which highlights the need for the epidemiological surveillance system to be updated, the importance of being prepared to face an epidemic and to develop a contingency plan.

Se ofrece una perspectiva de las epidemias y pandemias en México en tres periodos: fines del siglo XVIII y siglos XX y XXI, con el fin de analizar cómo las autoridades sanitarias y gubernamentales abordaron estos problemas, así como los desafíos que han representado. Se consultaron fuentes históricas documentales y, en los casos actuales, la participación en ellos. Se combinó metodología epidemiológica e histórica social. La presencia de las epidemias en México es una constante, lo cual evidencia la necesidad de actualizar el sistema de vigilancia epidemiológica, de estar preparados para enfrentar una epidemia y de elaborar un plan de contingencia.